ERBB2 and colonic neoplasm: It was demonstrated that CUR is able to inhibit EGFR and ErbB2 phosphorylation in breast and colon cancer cell lines and that the combined treatment of RES+CUR increases these effects in colon carcinoma cell lines [51].